Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): Study protocol for a randomized controlled trial

Andrew J. Nunn, I. D. Rusen, Armand Van Deun, Gabriela Torrea, Patrick P J Phillips, Chen Yuan Chiang, S. Bertel Squire, Jason Madan, Sarah K. Meredith

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background: In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are that patients should be treated for a minimum of 20 months. A series of cohort studies conducted in Bangladesh identified a nine-month regimen with very promising results. There is a need to evaluate this regimen in comparison with the currently recommended regimen in a randomized controlled trial in a variety of settings, including patients with HIV-coinfection.Methods/Design: STREAM is a multi-centre randomized trial of non-inferiority design comparing a nine-month regimen to the treatment currently recommended by the World Health Organization in patients with MDR pulmonary TB with no evidence on line probe assay of fluoroquinolone or kanamycin resistance. The nine-month regimen includes clofazimine and high-dose moxifloxacin and can be extended to 11 months in the event of delay in smear conversion. The primary outcome is based on the bacteriological status of the patients at 27 months post-randomization. Based on the assumption that the nine-month regimen will be slightly more effective than the control regimen and, given a 10% margin of non-inferiority, a total of 400 patients are required to be enrolled. Health economics data are being collected on all patients in selected sites.Discussion: The results from the study in Bangladesh and cohorts in progress elsewhere are encouraging, but for this regimen to be recommended more widely than in a research setting, robust evidence is needed from a randomized clinical trial. Results from the STREAM trial together with data from ongoing cohorts should provide the evidence necessary to revise current recommendations for the treatment for MDR-TB.Trial registration: This trial was registered with clincaltrials.gov (registration number: ISRCTN78372190) on 14 October 2010.

Original languageEnglish
Article number353
JournalTrials
Volume15
Issue number1
DOIs
Publication statusPublished - Sep 9 2014

Fingerprint

Multidrug-Resistant Tuberculosis
Tuberculosis
Randomized Controlled Trials
Pharmaceutical Preparations
Bangladesh
Therapeutics
Clofazimine
Kanamycin Resistance
Fluoroquinolones
Expert Testimony
Random Allocation
Coinfection
Cohort Studies
Economics
HIV
Guidelines
Lung
Health
Research

Keywords

  • Multi-drug-resistant tuberculosis
  • Multicenter randomized trial
  • Non-inferiority
  • Shorter treatment duration

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM) : Study protocol for a randomized controlled trial. / Nunn, Andrew J.; Rusen, I. D.; Van Deun, Armand; Torrea, Gabriela; Phillips, Patrick P J; Chiang, Chen Yuan; Squire, S. Bertel; Madan, Jason; Meredith, Sarah K.

In: Trials, Vol. 15, No. 1, 353, 09.09.2014.

Research output: Contribution to journalArticle

Nunn, Andrew J. ; Rusen, I. D. ; Van Deun, Armand ; Torrea, Gabriela ; Phillips, Patrick P J ; Chiang, Chen Yuan ; Squire, S. Bertel ; Madan, Jason ; Meredith, Sarah K. / Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM) : Study protocol for a randomized controlled trial. In: Trials. 2014 ; Vol. 15, No. 1.
@article{ed6b307deeb649daa7544b3030497a23,
title = "Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): Study protocol for a randomized controlled trial",
abstract = "Background: In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are that patients should be treated for a minimum of 20 months. A series of cohort studies conducted in Bangladesh identified a nine-month regimen with very promising results. There is a need to evaluate this regimen in comparison with the currently recommended regimen in a randomized controlled trial in a variety of settings, including patients with HIV-coinfection.Methods/Design: STREAM is a multi-centre randomized trial of non-inferiority design comparing a nine-month regimen to the treatment currently recommended by the World Health Organization in patients with MDR pulmonary TB with no evidence on line probe assay of fluoroquinolone or kanamycin resistance. The nine-month regimen includes clofazimine and high-dose moxifloxacin and can be extended to 11 months in the event of delay in smear conversion. The primary outcome is based on the bacteriological status of the patients at 27 months post-randomization. Based on the assumption that the nine-month regimen will be slightly more effective than the control regimen and, given a 10{\%} margin of non-inferiority, a total of 400 patients are required to be enrolled. Health economics data are being collected on all patients in selected sites.Discussion: The results from the study in Bangladesh and cohorts in progress elsewhere are encouraging, but for this regimen to be recommended more widely than in a research setting, robust evidence is needed from a randomized clinical trial. Results from the STREAM trial together with data from ongoing cohorts should provide the evidence necessary to revise current recommendations for the treatment for MDR-TB.Trial registration: This trial was registered with clincaltrials.gov (registration number: ISRCTN78372190) on 14 October 2010.",
keywords = "Multi-drug-resistant tuberculosis, Multicenter randomized trial, Non-inferiority, Shorter treatment duration",
author = "Nunn, {Andrew J.} and Rusen, {I. D.} and {Van Deun}, Armand and Gabriela Torrea and Phillips, {Patrick P J} and Chiang, {Chen Yuan} and Squire, {S. Bertel} and Jason Madan and Meredith, {Sarah K.}",
year = "2014",
month = "9",
day = "9",
doi = "10.1186/1745-6215-15-353",
language = "English",
volume = "15",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM)

T2 - Study protocol for a randomized controlled trial

AU - Nunn, Andrew J.

AU - Rusen, I. D.

AU - Van Deun, Armand

AU - Torrea, Gabriela

AU - Phillips, Patrick P J

AU - Chiang, Chen Yuan

AU - Squire, S. Bertel

AU - Madan, Jason

AU - Meredith, Sarah K.

PY - 2014/9/9

Y1 - 2014/9/9

N2 - Background: In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are that patients should be treated for a minimum of 20 months. A series of cohort studies conducted in Bangladesh identified a nine-month regimen with very promising results. There is a need to evaluate this regimen in comparison with the currently recommended regimen in a randomized controlled trial in a variety of settings, including patients with HIV-coinfection.Methods/Design: STREAM is a multi-centre randomized trial of non-inferiority design comparing a nine-month regimen to the treatment currently recommended by the World Health Organization in patients with MDR pulmonary TB with no evidence on line probe assay of fluoroquinolone or kanamycin resistance. The nine-month regimen includes clofazimine and high-dose moxifloxacin and can be extended to 11 months in the event of delay in smear conversion. The primary outcome is based on the bacteriological status of the patients at 27 months post-randomization. Based on the assumption that the nine-month regimen will be slightly more effective than the control regimen and, given a 10% margin of non-inferiority, a total of 400 patients are required to be enrolled. Health economics data are being collected on all patients in selected sites.Discussion: The results from the study in Bangladesh and cohorts in progress elsewhere are encouraging, but for this regimen to be recommended more widely than in a research setting, robust evidence is needed from a randomized clinical trial. Results from the STREAM trial together with data from ongoing cohorts should provide the evidence necessary to revise current recommendations for the treatment for MDR-TB.Trial registration: This trial was registered with clincaltrials.gov (registration number: ISRCTN78372190) on 14 October 2010.

AB - Background: In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are that patients should be treated for a minimum of 20 months. A series of cohort studies conducted in Bangladesh identified a nine-month regimen with very promising results. There is a need to evaluate this regimen in comparison with the currently recommended regimen in a randomized controlled trial in a variety of settings, including patients with HIV-coinfection.Methods/Design: STREAM is a multi-centre randomized trial of non-inferiority design comparing a nine-month regimen to the treatment currently recommended by the World Health Organization in patients with MDR pulmonary TB with no evidence on line probe assay of fluoroquinolone or kanamycin resistance. The nine-month regimen includes clofazimine and high-dose moxifloxacin and can be extended to 11 months in the event of delay in smear conversion. The primary outcome is based on the bacteriological status of the patients at 27 months post-randomization. Based on the assumption that the nine-month regimen will be slightly more effective than the control regimen and, given a 10% margin of non-inferiority, a total of 400 patients are required to be enrolled. Health economics data are being collected on all patients in selected sites.Discussion: The results from the study in Bangladesh and cohorts in progress elsewhere are encouraging, but for this regimen to be recommended more widely than in a research setting, robust evidence is needed from a randomized clinical trial. Results from the STREAM trial together with data from ongoing cohorts should provide the evidence necessary to revise current recommendations for the treatment for MDR-TB.Trial registration: This trial was registered with clincaltrials.gov (registration number: ISRCTN78372190) on 14 October 2010.

KW - Multi-drug-resistant tuberculosis

KW - Multicenter randomized trial

KW - Non-inferiority

KW - Shorter treatment duration

UR - http://www.scopus.com/inward/record.url?scp=84907022895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907022895&partnerID=8YFLogxK

U2 - 10.1186/1745-6215-15-353

DO - 10.1186/1745-6215-15-353

M3 - Article

C2 - 25199531

AN - SCOPUS:84907022895

VL - 15

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 353

ER -